| Symbol | CGTX |
|---|---|
| Name | COGNITION THERAPEUTICS INC |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biological Products, (No Diagnostic Substances) |
| Address | 2500 WESTCHESTER AVE, PURCHASE, NY 10577 |
| Telephone | 412-481-2210 |
| Fax | — |
| — | |
| Website | https://www.cogrx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001455365 |
| Description | Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate, CT1812, is an orally delivered, small molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex. Additional info from NASDAQ: |
2026-05-04 20:01
Doyle John Brendan 🔴 sold 8.6K shares of COGNITION THERAPEUTICS INC (CGTX) at $1.28 Transaction Date: May 01, 2026 | Filing ID: 054858
Read more
2026-04-27 17:11
New Form ARS - COGNITION THERAPEUTICS INC <b>Filed:</b> 2026-04-27 <b>AccNo:</b> 0001104659-26-049438 <b>Size:</b> 2 MB
Read more
2026-04-27 17:08
New Form DEFA14A - COGNITION THERAPEUTICS INC <b>Filed:</b> 2026-04-27 <b>AccNo:</b> 0001104659-26-049436 <b>Size:</b> 321 KB
Read more
2026-04-27 17:06
New Form DEF 14A - COGNITION THERAPEUTICS INC <b>Filed:</b> 2026-04-27 <b>AccNo:</b> 0001104659-26-049427 <b>Size:</b> 1 MB
Read more
2026-04-20 20:18
Doyle John Brendan 🟢 acquired 10.0K shares of COGNITION THERAPEUTICS INC (CGTX) at $1.13 Transaction Date: Apr 16, 2026 | Filing ID: 045511
Read more
2026-04-20 20:16
Director Ricciardi Lisa 🟢 acquired 9.2K shares of COGNITION THERAPEUTICS INC (CGTX) at $1.10 Transaction Date: Apr 16, 2026 | Filing ID: 045502
Read more
2026-04-07 11:30
Cognition Therapeutics to Present at Needham Virtual Healthcare Conference
Read more
2026-03-26 11:36
(90% Positive) COGNITION THERAPEUTICS INC (CGTX) Announces Enrollment Update for trial Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Efficacy Assessment
Read more
2026-03-26 11:30
Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06961760 | Expanded Access Program for CT1812 (Zervimesine) | — | Dementia With Lewy Bodies | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT07326124 | Stratification and Treatment in Early Psychosis Study -ASSIST | Phase3 | Treatment Resistant Psychosis | Not_Yet_Recruiting | 2026-06-01 | 2029-09-01 | ClinicalTrials.gov |
| NCT07531732 | Links Between Self-awareness and Sociocognitive Processes in Neurodegenerative … | — | Frontotemporal Dementia, Behavioral Variant | Recruiting | 2026-04-01 | 2027-12-01 | ClinicalTrials.gov |
| NCT07512375 | The Effectiveness of an ETP Programme in Myasthenia Gravis: a Proof-of-concept … | — | Myasthenia Gravis (MG) | Not_Yet_Recruiting | 2026-04-01 | 2027-06-01 | ClinicalTrials.gov |
| NCT07500909 | Study of the Role of Top-down Processes in Neuronal Reorganization and Recovery… | — | Deafness, Bilateral | Not_Yet_Recruiting | 2026-03-01 | 2029-03-01 | ClinicalTrials.gov |
| NCT06778564 | Stratification and Treatment in Early Psychosis Study - ENHANCE | Phase3 | Psychosis | Not_Yet_Recruiting | 2026-02-01 | 2029-02-01 | ClinicalTrials.gov |
| NCT05948579 | Department of Defense PTSD Adaptive Platform Trial - Intervention B - Vilazodone | Phase2 | Post Traumatic Stress Disorder | Not_Yet_Recruiting | 2025-11-01 | 2026-09-01 | ClinicalTrials.gov |
| NCT06816433 | Department of Defense PTSD Adaptive Platform Trial - Intervention D - SLS-002 | Phase2 | Post Traumatic Stress Disorder | Not_Yet_Recruiting | 2025-11-01 | 2026-09-01 | ClinicalTrials.gov |
| NCT06591780 | Innovative Multi-Variable Biofeedback for Improving Gait Performance in Individ… | Na | Diabetic Peripheral Neuropathy | Recruiting | 2025-10-20 | 2027-06-01 | ClinicalTrials.gov |
| NCT07531706 | Cortical Tracking of Speech in the First Year of Life | — | Language Development | Recruiting | 2025-10-14 | 2028-02-01 | ClinicalTrials.gov |
| NCT07207577 | Evaluation of Physiological and Psychological Factors Involved in Exercise Into… | Na | Beta Thalassemia Transfusion Dependent | Recruiting | 2025-09-04 | 2028-10-01 | ClinicalTrials.gov |
| NCT07064291 | Enhancing Self-Esteem in Patients With Multiple Sclerosis: A Randomised Control… | Na | Multiple Sclerosis | Not_Yet_Recruiting | 2025-09-01 | 2027-09-01 | ClinicalTrials.gov |
| NCT06507189 | Multidimensional Predictive Modeling to Understand Mechanisms of Exercise Respo… | Na | Aging | Recruiting | 2025-01-27 | 2029-08-31 | ClinicalTrials.gov |
| NCT05965336 | Walking Function in Diabetic Peripheral Neuropathy | Na | Diabetic Peripheral Neuropathy | Recruiting | 2024-12-05 | 2027-03-01 | ClinicalTrials.gov |
| NCT06600217 | Closed-loop Non-invasive Brain Stiumlation | — | Non-invasive Brain Stimulation | Not_Yet_Recruiting | 2024-10-01 | 2027-09-01 | ClinicalTrials.gov |
| NCT06422819 | Clinical Evaluation of HRV Biofeedback in Functional Neurological Disorders Com… | Na | Functional Neurological Disorder | Recruiting | 2024-09-09 | 2027-05-01 | ClinicalTrials.gov |
| NCT06391684 | Flexibility and the Predictive Brain in Autistic Males and Females | — | Autism Spectrum Disorder | Not_Yet_Recruiting | 2024-06-01 | 2028-12-01 | ClinicalTrials.gov |
| NCT07274722 | Influence of Control Deprivation on the Use of the Analytical Cognitive Style i… | Na | Anorexia Nervosa | Recruiting | 2024-04-04 | 2026-04-03 | ClinicalTrials.gov |
| NCT06321380 | Working Memory Functioning in Alzheimer's Disease and Vascular Dementia | — | Alzheimer Disease | Unknown | 2024-04-01 | 2025-10-01 | ClinicalTrials.gov |
| NCT06194864 | Drug Interaction Study | Phase1 | Drug Interaction | Completed | 2024-01-18 | 2024-05-22 | ClinicalTrials.gov |
| NCT05948553 | Department of Defense PTSD Adaptive Platform Trial - Intervention A - Fluoxetine | Phase2 | Post Traumatic Stress Disorder | Recruiting | 2023-11-02 | 2026-09-01 | ClinicalTrials.gov |
| NCT05531656 | A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Dise… | Phase2 | Early Alzheimer's Disease | Active_Not_Recruiting | 2023-06-28 | 2027-04-01 | ClinicalTrials.gov |
| NCT05893537 | Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With G… | Phase2 | Age-Related Macular Degeneration | Terminated | 2023-06-16 | 2025-03-28 | ClinicalTrials.gov |
| NCT05833529 | Innovative Cognitive and Behavioral Psychotherapy for Cocaine Use Disorder | Na | Cocaine Use Disorder | Recruiting | 2023-05-01 | 2025-05-01 | ClinicalTrials.gov |
| NCT07304843 | A Two-part Study to Investigate the Effects in Adults of Two Doses of Golexanol… | Phase1 | Primary Biliary Cholangitis (PBC) | Recruiting | 2023-04-14 | 2026-06-30 | ClinicalTrials.gov |
| NCT06648538 | Evaluation of a Therapeutic Education Application in the Treatment of Young Peo… | Na | Internet Addiction Disorder | Completed | 2023-03-03 | 2024-01-16 | ClinicalTrials.gov |
| NCT04738838 | Oxytocin on Cold Water Task Performance and Recovery | Phase2 | Cold Exposure | Completed | 2022-05-20 | 2022-07-29 | ClinicalTrials.gov |
| NCT05225415 | Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects W… | Phase2 | Dementia With Lewy Bodies | Completed | 2022-05-19 | 2024-11-25 | ClinicalTrials.gov |
| NCT04433351 | Sensory-Motor Integration for Speech Rehabilitation in Patients with Post-strok… | Na | Aphasia Non Fluent | Recruiting | 2022-05-05 | 2026-03-01 | ClinicalTrials.gov |
| NCT05248672 | Study to Assess the Pharmacokinetics of CT1812 in Older Healthy Volunteers | Phase1 | Alzheimer Disease | Completed | 2022-02-15 | 2022-06-01 | ClinicalTrials.gov |
| NCT04981626 | Interoception in Anorexia Nervosa | — | Anorexia | Unknown | 2022-02-14 | 2023-04-01 | ClinicalTrials.gov |
| NCT04732247 | Oxytocin for Oxidative Stress and Inflammation | Phase2 | Oxidative Stress | Completed | 2022-02-01 | 2023-09-15 | ClinicalTrials.gov |
| NCT05225389 | Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT18… | Phase1 | Alzheimer Disease | Completed | 2021-12-31 | 2022-01-24 | ClinicalTrials.gov |
| NCT05109481 | Masks and Visual Preferences in the Newborn | — | Newborn | Unknown | 2021-11-15 | 2022-12-15 | ClinicalTrials.gov |
| NCT05047952 | Vortioxetine for Post-COVID-19 Condition | Phase2 | Post-COVID-19 Condition | Completed | 2021-09-16 | 2023-02-22 | ClinicalTrials.gov |
| NCT04562974 | Representational Approach to Hippocampal Functions : a fMRI Study | Na | Memory, Episodic | Completed | 2021-09-03 | 2022-03-02 | ClinicalTrials.gov |
| NCT05557149 | Virtual Reality Exposure and Respiratory Relaxation-Based Coping With Cocaine C… | Na | Virtual Reality Exposure Therapy | Completed | 2021-03-31 | 2021-07-29 | ClinicalTrials.gov |
| NCT04807933 | Neurovegetative Decoupling in Somatoform Disorders : Biofeedback Interest | Na | Somatoform Disorders | Terminated | 2021-03-16 | 2023-09-05 | ClinicalTrials.gov |
| NCT04714905 | Better Understanding the Metamorphosis of Pregnancy (BUMP) | — | Pregnancy Related | Completed | 2021-02-23 | 2023-07-03 | ClinicalTrials.gov |
| NCT04180709 | CBT to Reduce Insomnia and Improve Social Recovery in Early Psychosis | Na | Psychotic Disorders | Completed | 2020-10-30 | 2023-07-31 | ClinicalTrials.gov |
| NCT04547569 | Somesthesic Role of the Ventro-lateral Prefrontal Cortex in Speech Motor Learni… | Na | Speech | Completed | 2020-10-20 | 2021-07-06 | ClinicalTrials.gov |
| NCT04069676 | Emotional Proactive Brain Study in Adults With Autism Spectrum Condition | — | Autism Spectrum Disorder | Completed | 2020-09-17 | 2021-07-12 | ClinicalTrials.gov |
| NCT04513743 | Ultra Long-Term Sleep Monitoring Using UNEEG™ Medical 24/7 EEG™ SubQ | Na | Sleep | Completed | 2020-09-07 | 2022-07-04 | ClinicalTrials.gov |
| NCT04735536 | Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEG | Phase2 | Alzheimer Disease | Completed | 2020-07-09 | 2023-04-26 | ClinicalTrials.gov |
| NCT04713111 | Stress and Recovery in Frontline COVID-19 Workers | Na | Covid19 | Completed | 2020-05-04 | 2020-11-30 | ClinicalTrials.gov |
| NCT04161261 | Minimizing Facial Nerve Stimulation in Cochlear Implants | Na | Cochlear Hearing Loss | Unknown | 2019-12-13 | 2022-11-01 | ClinicalTrials.gov |
| NCT04209296 | Chart Review of Patients Undergoing Ketamine Infusions | — | Major Depressive Disorder | Completed | 2019-12-03 | 2023-09-14 | ClinicalTrials.gov |
| NCT03939676 | Evaluating Motivation and Reward Mechanisms and Brain Substrates in Adults With… | — | Anhedonia | Completed | 2019-10-30 | 2020-12-15 | ClinicalTrials.gov |
| NCT04036162 | Spatial and Dynamic Characterization of Brain Activity for Language and Posture… | Na | Healthy Volunteers | Completed | 2019-10-01 | 2021-06-22 | ClinicalTrials.gov |
| NCT03999567 | Validation Study: Mobile DSST on Cognition in Adults With MDD | Na | Major Depressive Episode | Completed | 2019-08-25 | 2020-02-04 | ClinicalTrials.gov |
| NCT03827057 | RECONsolidation of Traumatic Memories to ResOLve Post Traumatic Stress Disorder… | Phase2 | Posttraumatic Stress Disorder | Completed | 2019-06-12 | 2025-05-06 | ClinicalTrials.gov |
| NCT03923569 | Epileptiform Activity During REM Sleep in Alzheimer's Disease | Na | Alzheimer Disease, Early Onset | Unknown | 2019-04-29 | 2023-06-01 | ClinicalTrials.gov |
| NCT03776513 | Neuro-cognitive Impact of Juvenile Obesity | Na | Pediatric Obesity | Unknown | 2018-12-12 | 2020-12-12 | ClinicalTrials.gov |
| NCT03538158 | A Personalized Health Behavior System | Na | Social Isolation | Completed | 2018-11-26 | 2021-10-26 | ClinicalTrials.gov |
| NCT03507790 | A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to … | Phase2 | Mild to Moderate Alzheimer's Disease | Completed | 2018-10-10 | 2024-05-29 | ClinicalTrials.gov |
| NCT03659825 | Ketone Esters for Optimization of Cognitive Performance in Hypoxia | Na | Hypoxia | Unknown | 2018-09-01 | 2018-11-15 | ClinicalTrials.gov |
| NCT03634709 | Autobiographical Memory Flexibility Training (MemFlex) for Posttraumatic Stress… | Na | Post Traumatic Stress Disorder | Completed | 2018-08-19 | 2020-05-11 | ClinicalTrials.gov |
| NCT03522129 | Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displ… | Phase1 | Alzheimer Disease | Completed | 2018-05-30 | 2019-02-06 | ClinicalTrials.gov |
| NCT03493282 | Effect of CT1812 Treatment on Brain Synaptic Density | Phase1 | Alzheimer Disease | Completed | 2018-03-28 | 2020-10-16 | ClinicalTrials.gov |
| NCT02053207 | Feasibility Study of Preoperative Cognitive Training in Cardiac Surgical Patien… | Na | Postoperative Cognitive Dysfunction | Unknown | 2018-01-01 | 2018-12-01 | ClinicalTrials.gov |
| NCT03117413 | Positron Emission Tomography Imaging of Brain Reorganisation of the Central Aud… | Na | Profound Hearing Impairment | Completed | 2017-11-23 | 2019-03-22 | ClinicalTrials.gov |
| NCT03543267 | Study on Neurocognitive Plasticity in Patients With Focal and Drug-resistant Ep… | Na | Epilepsy | Completed | 2017-10-21 | 2022-07-05 | ClinicalTrials.gov |
| NCT03053362 | THINC-it Vortioxetine - Sensitivity to Change | Phase2 | Major Depressive Disorder | Completed | 2017-05-24 | 2018-08-08 | ClinicalTrials.gov |
| NCT03661190 | Online Grammatical Reasoning Training for Older Adults | Na | Healthy Aging | Completed | 2017-03-31 | 2018-11-30 | ClinicalTrials.gov |
| NCT03133117 | Deficits, Adaptation and Cerebral Functional Reorganization of Visual Retinotop… | Na | Macular Degeneration | Terminated | 2017-02-02 | 2018-05-25 | ClinicalTrials.gov |
| NCT03716427 | Drug Interaction Study of CT1812 in Healthy Volunteers | Phase1 | Healthy Volunteers | Completed | 2016-11-10 | 2017-02-15 | ClinicalTrials.gov |
| NCT03012685 | Sleep and Wellbeing Study | — | Sleep | Completed | 2016-11-01 | 2018-04-01 | ClinicalTrials.gov |
| NCT02907567 | Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease | Phase1 | Alzheimer's Disease | Completed | 2016-09-01 | 2017-09-01 | ClinicalTrials.gov |
| NCT02614326 | MemFlex to Prevent Depressive Relapse | Phase2 | Major Depressive Disorder | Completed | 2016-01-01 | 2020-12-01 | ClinicalTrials.gov |
| NCT02675075 | DESIPHER_Speech Degradation as an Indicator of Physiological Degeneration in ALS | — | Amyotrophic Lateral Sclerosis | Completed | 2016-01-01 | 2017-12-31 | ClinicalTrials.gov |
| NCT02508493 | Validation of the THINC-it Tool for Cognitive Dysfunction in Major Depressive D… | — | Major Depressive Disorder | Completed | 2015-11-01 | 2016-07-01 | ClinicalTrials.gov |
| NCT02590796 | Validating Studies to Assess the Diagnostic Accuracy of a Software Application … | — | Delirium | Completed | 2015-10-12 | 2018-03-22 | ClinicalTrials.gov |
| NCT02597686 | The STAGE Study for Bipolar Disorder | Na | Bipolar Disorder | Unknown | 2015-10-01 | 2016-09-01 | ClinicalTrials.gov |
| NCT02570997 | Ascending Dose Study of CT1812 in Healthy Volunteers | Phase1 | Cognitive Impairment | Completed | 2015-09-01 | — | ClinicalTrials.gov |
| NCT02603380 | Feasibility of a Software App for Testing Inattention in Delirium | — | Delirium | Completed | 2015-03-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT02371291 | Memory Flexibility Training for Depression | Phase1 | Major Depressive Disorder | Completed | 2015-01-01 | 2017-01-01 | ClinicalTrials.gov |
| NCT02756065 | Connectomics in Psychiatric Classification of Bipolar Disorder and Schizophrenia | — | Bipolar Disorder | Completed | 2014-09-01 | 2019-08-01 | ClinicalTrials.gov |
| NCT02416245 | Impact of Beverage Powder With Micronutrients and Brahmi Extract on Cognitive V… | Na | Cognition | Completed | 2014-07-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT02080351 | A Simple Cognitive Task to Reduce the Build-Up of Flashbacks After a Road Traff… | Na | Post-traumatic Stress Disorders | Completed | 2014-03-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01981018 | MAPP: Imagery-focused Therapy for Bipolar Disorder | Na | Bipolar Disorder | Completed | 2013-11-01 | 2015-07-01 | ClinicalTrials.gov |
| NCT02502513 | Prevention of Intrusive Memories and Posttraumatic Stress Symptoms After Emerge… | Na | Posttraumatic Stress Disorder | Completed | 2013-06-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT02083978 | Bipolar Research Study Using MR Imaging | — | Bipolar Affective Disorder | Completed | 2010-01-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01070004 | Effect of Countermeasures on Nocturnal Driving Performance | Na | Sleepiness | Completed | 2010-01-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT00903643 | Sensory Processing in Subjects With Painful Bladder Syndrome | — | Painful Bladder Syndrome | Completed | 2008-05-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT00736567 | Evaluation of a Diagnostic Enteric Card for Management of Diarrhea | — | Diarrhea | Completed | 2008-05-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00529581 | A Study of C105 on Cognitive Dysfunction in Persons With Multiple Sclerosis | Phase2 | Cognition Disorders | Completed | 2006-11-01 | 2008-04-01 | ClinicalTrials.gov |
Total clinical trials: 86
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Card Pairs | Other | Approved | Healthy Aging | COMPLETED | NCT03661190 |
| Grammatical Reasoning | Other | Approved | Healthy Aging | COMPLETED | NCT03661190 |
| Card Pairs | Other | Approved | Healthy Aging | COMPLETED | NCT03661190 |
| Grammatical Reasoning | Other | Approved | Healthy Aging | COMPLETED | NCT03661190 |
| Card Pairs | Other | Approved | Healthy Aging | COMPLETED | NCT03661190 |
| Grammatical Reasoning | Other | Approved | Healthy Aging | COMPLETED | NCT03661190 |
| Card Pairs | Other | Approved | Healthy Aging | COMPLETED | NCT03661190 |
| Grammatical Reasoning | Other | Approved | Healthy Aging | COMPLETED | NCT03661190 |
| Card Pairs | Other | Approved | Healthy Aging | COMPLETED | NCT03661190 |
| Grammatical Reasoning | Other | Approved | Healthy Aging | COMPLETED | NCT03661190 |
| Card Pairs | Other | Approved | Healthy Aging | COMPLETED | NCT03661190 |
| Grammatical Reasoning | Other | Approved | Healthy Aging | COMPLETED | NCT03661190 |
| Card Pairs | Other | Approved | Healthy Aging | COMPLETED | NCT03661190 |
| Grammatical Reasoning | Other | Approved | Healthy Aging | COMPLETED | NCT03661190 |
| Card Pairs | Other | Approved | Healthy Aging | COMPLETED | NCT03661190 |
| Grammatical Reasoning | Other | Approved | Healthy Aging | COMPLETED | NCT03661190 |
| Card Pairs | Other | Approved | Healthy Aging | COMPLETED | NCT03661190 |
| Grammatical Reasoning | Other | Approved | Healthy Aging | COMPLETED | NCT03661190 |
| Electronic Digit Symbol Substitution Test (DSST)- (a.k.a. Codebreaker) | Other | Approved | Major Depressive Episode | COMPLETED | NCT03999567 |
| Pen and Paper Digit Symbol Substitution Test (DSST) | Other | Approved | Major Depressive Episode | COMPLETED | NCT03999567 |
| Electronic Digit Symbol Substitution Test (DSST)- (a.k.a. Codebreaker) | Other | Approved | Major Depressive Episode | COMPLETED | NCT03999567 |
| Pen and Paper Digit Symbol Substitution Test (DSST) | Other | Approved | Major Depressive Episode | COMPLETED | NCT03999567 |
| Driving simulator | Other | Approved | Sleepiness | COMPLETED | NCT01070004 |
| Real driving situation | Other | Approved | Sleepiness | COMPLETED | NCT01070004 |
| Driving simulator | Other | Approved | Sleepiness | COMPLETED | NCT01070004 |
| Real driving situation | Other | Approved | Sleepiness | COMPLETED | NCT01070004 |
| Physical examination | Other | Preclinical | Painful Bladder Syndrome | COMPLETED | NCT00903643 |
| Physical examination | Other | Preclinical | Painful Bladder Syndrome | COMPLETED | NCT00903643 |
| Standard radiological assessment | Other | Approved | Dementia | UNKNOWN | NCT02286505 |
| Brain Morphometry | Other | Approved | Dementia | UNKNOWN | NCT02286505 |
| Standard radiological assessment | Other | Approved | Dementia | UNKNOWN | NCT02286505 |
| Brain Morphometry | Other | Approved | Dementia | UNKNOWN | NCT02286505 |
| Simple cognitive task | Other | Approved | Post-traumatic Stress Disorders | COMPLETED | NCT02080351 |
| Simple cognitive task | Other | Approved | Post-traumatic Stress Disorders | COMPLETED | NCT02080351 |
| MRI scanning | Other | Preclinical | Bipolar Affective Disorder | COMPLETED | NCT02083978 |
| MRI scanning | Other | Preclinical | Bipolar Affective Disorder | COMPLETED | NCT02083978 |
| Non fortified isocaloric control (without added micronutrients and Bacopa monnieri extract) | Other | Approved | Cognition | COMPLETED | NCT02416245 |
| Beverage powder fortified with micronutrients and Bacopa monnieri extract | Other | Approved | Cognition | COMPLETED | NCT02416245 |
| Non fortified isocaloric control (without added micronutrients and Bacopa monnieri extract) | Other | Approved | Cognition | COMPLETED | NCT02416245 |
| Beverage powder fortified with micronutrients and Bacopa monnieri extract | Other | Approved | Cognition | COMPLETED | NCT02416245 |
| Imagery-focused Cognitive Therapy (ImCT - psychotherapy based on CBT principles) | Drug | Approved | Bipolar Disorder | COMPLETED | NCT01981018 |
| Imagery-focused Cognitive Therapy (ImCT - psychotherapy based on CBT principles) | Drug | Approved | Bipolar Disorder | COMPLETED | NCT01981018 |
| No intervention | Other | Preclinical | Delirium | COMPLETED | NCT02603380 |
| No intervention | Other | Preclinical | Delirium | COMPLETED | NCT02603380 |
| No intervention | Other | Preclinical | Delirium | COMPLETED | NCT02603380 |
| Brief computerized intervention | Other | Approved | Posttraumatic Stress Disorder | COMPLETED | NCT02502513 |
| Brief computerized intervention | Other | Approved | Posttraumatic Stress Disorder | COMPLETED | NCT02502513 |
| Brief computerized intervention | Other | Approved | Posttraumatic Stress Disorder | COMPLETED | NCT02502513 |
| SD-PB training | Other | Approved | Bipolar Disorder | UNKNOWN | NCT02597686 |
| SD-PB training | Other | Approved | Bipolar Disorder | UNKNOWN | NCT02597686 |
| Placebo | Other | Phase PHASE1 | Cognitive Impairment | COMPLETED | NCT02570997 |
| CT1812 | Other | Phase PHASE1 | Cognitive Impairment | COMPLETED | NCT02570997 |
| Psychoeducation | Other | Phase PHASE1 | Major Depressive Disorder | COMPLETED | NCT02371291 |
| Memory Flexibility Training | Other | Phase PHASE1 | Major Depressive Disorder | COMPLETED | NCT02371291 |
| Psychoeducation | Other | Phase PHASE1 | Major Depressive Disorder | COMPLETED | NCT02371291 |
| Memory Flexibility Training | Other | Phase PHASE1 | Major Depressive Disorder | COMPLETED | NCT02371291 |
| Cog-Train Intervention | Other | Approved | Postoperative Cognitive Dysfunction | UNKNOWN | NCT02053207 |
| Cog-Train Intervention | Other | Approved | Postoperative Cognitive Dysfunction | UNKNOWN | NCT02053207 |
| No intervention given to participants | Other | Preclinical | Delirium | COMPLETED | NCT02590796 |
| No intervention given to participants | Other | Preclinical | Delirium | COMPLETED | NCT02590796 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT02907567 |
| CT1812 | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT02907567 |
| Hypoxic exposure | Other | Approved | Hypoxia | UNKNOWN | NCT03659825 |
| Taste Matched Placebo | Other | Approved | Hypoxia | UNKNOWN | NCT03659825 |
| Ketone Ester | Other | Approved | Hypoxia | UNKNOWN | NCT03659825 |
| Hypoxic exposure | Other | Approved | Hypoxia | UNKNOWN | NCT03659825 |
| Taste Matched Placebo | Other | Approved | Hypoxia | UNKNOWN | NCT03659825 |
| Ketone Ester | Other | Approved | Hypoxia | UNKNOWN | NCT03659825 |
| midazolam | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03716427 |
| Omeprazole | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03716427 |
| dextromethorphan | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03716427 |
| tolbutamide | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03716427 |
| CT1812 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03716427 |
| an MRI examination | Other | Approved | Pediatric Obesity | UNKNOWN | NCT03776513 |
| an MRI examination | Other | Approved | Pediatric Obesity | UNKNOWN | NCT03776513 |
| Card Pairs | Other | Approved | Healthy Aging | COMPLETED | NCT03661190 |
| Grammatical Reasoning | Other | Approved | Healthy Aging | COMPLETED | NCT03661190 |
| Card Pairs | Other | Approved | Healthy Aging | COMPLETED | NCT03661190 |
| Grammatical Reasoning | Other | Approved | Healthy Aging | COMPLETED | NCT03661190 |
| Functional Magnetic Resonance Imaging (fMRI) | Other | Approved | Macular Degeneration | TERMINATED | NCT03133117 |
| Functional Magnetic Resonance Imaging (fMRI) | Other | Approved | Macular Degeneration | TERMINATED | NCT03133117 |
| Memory Flexibility training (MemFlex) | Other | Approved | Post Traumatic Stress Disorder | COMPLETED | NCT03634709 |
| Memory Flexibility training (MemFlex) | Other | Approved | Post Traumatic Stress Disorder | COMPLETED | NCT03634709 |
| no intervention | Other | Preclinical | Bipolar Disorder | COMPLETED | NCT02756065 |
| no intervention | Other | Preclinical | Bipolar Disorder | COMPLETED | NCT02756065 |
| no intervention | Other | Preclinical | Bipolar Disorder | COMPLETED | NCT02756065 |
| Lifestyle (Exercise) | Other | Approved | Covid19 | COMPLETED | NCT04713111 |
| Lifestyle (Meditation) | Other | Approved | Covid19 | COMPLETED | NCT04713111 |
| Lifestyle (Exercise) | Other | Approved | Covid19 | COMPLETED | NCT04713111 |
| Lifestyle (Meditation) | Other | Approved | Covid19 | COMPLETED | NCT04713111 |
| Psychoeducation | Other | Phase PHASE2 | Major Depressive Disorder | COMPLETED | NCT02614326 |
| Autobiographical Memory Flexibility (MemFlex) training | Other | Phase PHASE2 | Major Depressive Disorder | COMPLETED | NCT02614326 |
| Psychoeducation | Other | Phase PHASE2 | Major Depressive Disorder | COMPLETED | NCT02614326 |
| Autobiographical Memory Flexibility (MemFlex) training | Other | Phase PHASE2 | Major Depressive Disorder | COMPLETED | NCT02614326 |
| Psychoeducation | Other | Phase PHASE2 | Major Depressive Disorder | COMPLETED | NCT02614326 |
| Autobiographical Memory Flexibility (MemFlex) training | Other | Phase PHASE2 | Major Depressive Disorder | COMPLETED | NCT02614326 |
| neuropsychological evaluation | Other | Approved | Alzheimer Disease, Early Onset | UNKNOWN | NCT03923569 |
| high-resolution MRI scan | Other | Approved | Alzheimer Disease, Early Onset | UNKNOWN | NCT03923569 |
| blood sample | Other | Approved | Alzheimer Disease, Early Onset | UNKNOWN | NCT03923569 |
| Overnight polysomnography | Other | Approved | Alzheimer Disease, Early Onset | UNKNOWN | NCT03923569 |
| neuropsychological evaluation | Other | Approved | Alzheimer Disease, Early Onset | UNKNOWN | NCT03923569 |
| high-resolution MRI scan | Other | Approved | Alzheimer Disease, Early Onset | UNKNOWN | NCT03923569 |
| blood sample | Other | Approved | Alzheimer Disease, Early Onset | UNKNOWN | NCT03923569 |
| Overnight polysomnography | Other | Approved | Alzheimer Disease, Early Onset | UNKNOWN | NCT03923569 |
| Electrical Stimulation | Other | Approved | Cochlear Hearing Loss | UNKNOWN | NCT04161261 |
| Electrical Stimulation | Other | Approved | Cochlear Hearing Loss | UNKNOWN | NCT04161261 |
| Pencil-and-paper Cognitive Tests | Other | Preclinical | Major Depressive Disorder | COMPLETED | NCT02508493 |
| THINC-it Tool | Other | Preclinical | Major Depressive Disorder | COMPLETED | NCT02508493 |
| Pencil-and-paper Cognitive Tests | Other | Preclinical | Major Depressive Disorder | COMPLETED | NCT02508493 |
| THINC-it Tool | Other | Preclinical | Major Depressive Disorder | COMPLETED | NCT02508493 |
| Pencil-and-paper Cognitive Tests | Other | Preclinical | Major Depressive Disorder | COMPLETED | NCT02508493 |
| THINC-it Tool | Other | Preclinical | Major Depressive Disorder | COMPLETED | NCT02508493 |
| Placebo | Other | Phase PHASE1 | Alzheimer Disease | COMPLETED | NCT03522129 |
| CT1812 | Other | Phase PHASE1 | Alzheimer Disease | COMPLETED | NCT03522129 |
| EEG | Other | Preclinical | Autism Spectrum Disorder | COMPLETED | NCT04069676 |
| EEG | Other | Preclinical | Autism Spectrum Disorder | COMPLETED | NCT04069676 |
| EEG | Other | Preclinical | Autism Spectrum Disorder | COMPLETED | NCT04069676 |
| Cognitive tasks | Other | Approved | Healthy Volunteers | COMPLETED | NCT04036162 |
| Cognitive tasks | Other | Approved | Healthy Volunteers | COMPLETED | NCT04036162 |
| Speech production | Other | Approved | Speech | COMPLETED | NCT04547569 |
| fMRI | Other | Approved | Speech | COMPLETED | NCT04547569 |
| Vibrotactile Discrimination | Other | Approved | Speech | COMPLETED | NCT04547569 |
| Speech adaptation | Other | Approved | Speech | COMPLETED | NCT04547569 |
| Speech production | Other | Approved | Speech | COMPLETED | NCT04547569 |
| fMRI | Other | Approved | Speech | COMPLETED | NCT04547569 |
| Vibrotactile Discrimination | Other | Approved | Speech | COMPLETED | NCT04547569 |
| Speech adaptation | Other | Approved | Speech | COMPLETED | NCT04547569 |
| Clinical and experimental session | Other | Preclinical | Anorexia | UNKNOWN | NCT04981626 |
| Clinical and experimental session | Other | Preclinical | Anorexia | UNKNOWN | NCT04981626 |
| Virtual Reality Exposure to Cocaine-Related Cues | Other | Approved | Virtual Reality Exposure Therapy | COMPLETED | NCT05557149 |
| Respiratory Relaxation | Other | Approved | Virtual Reality Exposure Therapy | COMPLETED | NCT05557149 |
| Virtual Reality Exposure to Neutral Cues | Other | Approved | Virtual Reality Exposure Therapy | COMPLETED | NCT05557149 |
| Virtual Reality Exposure to Cocaine-Related Cues | Other | Approved | Virtual Reality Exposure Therapy | COMPLETED | NCT05557149 |
| Respiratory Relaxation | Other | Approved | Virtual Reality Exposure Therapy | COMPLETED | NCT05557149 |
| Virtual Reality Exposure to Neutral Cues | Other | Approved | Virtual Reality Exposure Therapy | COMPLETED | NCT05557149 |
| Control Condition | Other | Approved | Social Isolation | COMPLETED | NCT03538158 |
| Intervention Condition | Other | Approved | Social Isolation | COMPLETED | NCT03538158 |
| Control Condition | Other | Approved | Social Isolation | COMPLETED | NCT03538158 |
| Intervention Condition | Other | Approved | Social Isolation | COMPLETED | NCT03538158 |
| Control Condition | Other | Approved | Social Isolation | COMPLETED | NCT03538158 |
| Intervention Condition | Other | Approved | Social Isolation | COMPLETED | NCT03538158 |
| CT1812 | Other | Phase PHASE1 | Alzheimer Disease | COMPLETED | NCT05248672 |
| 300 mg [C14] CT1812 | Other | Phase PHASE1 | Alzheimer Disease | COMPLETED | NCT05225389 |
| Sleepio | Other | Approved | Psychotic Disorders | COMPLETED | NCT04180709 |
| Placebo | Other | Phase PHASE1 | Alzheimer Disease | COMPLETED | NCT03493282 |
| Active Treatment- CT1812 300 mg | Drug | Phase PHASE1 | Alzheimer Disease | COMPLETED | NCT03493282 |
| Active Treatment- CT1812 100 mg | Drug | Phase PHASE1 | Alzheimer Disease | COMPLETED | NCT03493282 |
| 24/7 EEG™ SubQ | Other | Approved | Sleep | COMPLETED | NCT04513743 |
| 24/7 EEG™ SubQ | Other | Approved | Sleep | COMPLETED | NCT04513743 |
| Placebo nasal spray | Other | Phase PHASE2 | Oxidative Stress | COMPLETED | NCT04732247 |
| Oxytocin nasal spray | Other | Phase PHASE2 | Oxidative Stress | COMPLETED | NCT04732247 |
| Placebo nasal spray | Other | Phase PHASE2 | Oxidative Stress | COMPLETED | NCT04732247 |
| Oxytocin nasal spray | Other | Phase PHASE2 | Oxidative Stress | COMPLETED | NCT04732247 |
| Clinical neurospychological assessement | Other | Preclinical | Alzheimer Disease | UNKNOWN | NCT06321380 |
| Clinical neuropsychological assessment | Other | Preclinical | Alzheimer Disease | UNKNOWN | NCT06321380 |
| Complex span task | Other | Preclinical | Alzheimer Disease | UNKNOWN | NCT06321380 |
| Clinical neurospychological assessement | Other | Preclinical | Alzheimer Disease | UNKNOWN | NCT06321380 |
| Clinical neuropsychological assessment | Other | Preclinical | Alzheimer Disease | UNKNOWN | NCT06321380 |
| Complex span task | Other | Preclinical | Alzheimer Disease | UNKNOWN | NCT06321380 |
| Social/non social; predictable vs unpredictable | Other | Preclinical | Autism Spectrum Disorder | NOT_YET_RECRUITING | NCT06391684 |
| Social/non social; predictable vs unpredictable | Other | Preclinical | Autism Spectrum Disorder | NOT_YET_RECRUITING | NCT06391684 |
| Pictures-based Cue Exposure (PCE) Therapy for Cocaine Craving - 3 weeks | Drug | Approved | Cocaine Use Disorder | RECRUITING | NCT05833529 |
| Memory Focused Cognitive Therapy (MFCT) - 1 week | Drug | Approved | Cocaine Use Disorder | RECRUITING | NCT05833529 |
| Virtual Reality Cue Exposure (VRCE) Therapy for Cocaine Craving - 2 weeks | Drug | Approved | Cocaine Use Disorder | RECRUITING | NCT05833529 |
| Pictures-based Cue Exposure (PCE) Therapy for Cocaine Craving - 3 weeks | Drug | Approved | Cocaine Use Disorder | RECRUITING | NCT05833529 |
| Memory Focused Cognitive Therapy (MFCT) - 1 week | Drug | Approved | Cocaine Use Disorder | RECRUITING | NCT05833529 |
| Virtual Reality Cue Exposure (VRCE) Therapy for Cocaine Craving - 2 weeks | Drug | Approved | Cocaine Use Disorder | RECRUITING | NCT05833529 |
| Pictures-based Cue Exposure (PCE) Therapy for Cocaine Craving - 3 weeks | Drug | Approved | Cocaine Use Disorder | RECRUITING | NCT05833529 |
| Memory Focused Cognitive Therapy (MFCT) - 1 week | Drug | Approved | Cocaine Use Disorder | RECRUITING | NCT05833529 |
| Virtual Reality Cue Exposure (VRCE) Therapy for Cocaine Craving - 2 weeks | Drug | Approved | Cocaine Use Disorder | RECRUITING | NCT05833529 |
| Ketamine Hydrochloride | Other | Preclinical | Major Depressive Disorder | COMPLETED | NCT04209296 |
| Ketamine Hydrochloride | Other | Preclinical | Major Depressive Disorder | COMPLETED | NCT04209296 |
| Pseudo HRV-BFB | Other | Approved | Functional Neurological Disorder | RECRUITING | NCT06422819 |
| Heart rate variability Biofeedback [HRV-BFB] | Other | Approved | Functional Neurological Disorder | RECRUITING | NCT06422819 |
| Pseudo HRV-BFB | Other | Approved | Functional Neurological Disorder | RECRUITING | NCT06422819 |
| Heart rate variability Biofeedback [HRV-BFB] | Other | Approved | Functional Neurological Disorder | RECRUITING | NCT06422819 |
| Ecopipam | Other | Phase PHASE1 | Drug Interaction | COMPLETED | NCT06194864 |
| rifampicin | Other | Phase PHASE1 | Drug Interaction | COMPLETED | NCT06194864 |
| Itraconazole | Other | Phase PHASE1 | Drug Interaction | COMPLETED | NCT06194864 |
| Ecopipam | Other | Phase PHASE1 | Drug Interaction | COMPLETED | NCT06194864 |
| rifampicin | Other | Phase PHASE1 | Drug Interaction | COMPLETED | NCT06194864 |
| Itraconazole | Other | Phase PHASE1 | Drug Interaction | COMPLETED | NCT06194864 |
| Phonix Care | Other | Approved | Internet Addiction Disorder | COMPLETED | NCT06648538 |
| Phonix Care | Other | Approved | Internet Addiction Disorder | COMPLETED | NCT06648538 |
| Placebo | Other | Phase PHASE2 | Alzheimer Disease | COMPLETED | NCT04735536 |
| CT1812 | Other | Phase PHASE2 | Alzheimer Disease | COMPLETED | NCT04735536 |
| Heart rate variability Biofeedback [HRV-BFB] | Other | Approved | Somatoform Disorders | TERMINATED | NCT04807933 |
| Heart rate variability Biofeedback [HRV-BFB] | Other | Approved | Somatoform Disorders | TERMINATED | NCT04807933 |
| Placebo | Other | Phase PHASE2 | Post-COVID-19 Condition | COMPLETED | NCT05047952 |
| Vortioxetine | Other | Phase PHASE2 | Post-COVID-19 Condition | COMPLETED | NCT05047952 |
| Placebo | Other | Phase PHASE2 | Post-COVID-19 Condition | COMPLETED | NCT05047952 |
| Vortioxetine | Other | Phase PHASE2 | Post-COVID-19 Condition | COMPLETED | NCT05047952 |
| Placebo | Other | Phase PHASE2 | Post-COVID-19 Condition | COMPLETED | NCT05047952 |
| Vortioxetine | Other | Phase PHASE2 | Post-COVID-19 Condition | COMPLETED | NCT05047952 |
| Simple rehabilitation | Other | Approved | Aphasia Non Fluent | RECRUITING | NCT04433351 |
| Enriched rehabilitation | Other | Approved | Aphasia Non Fluent | RECRUITING | NCT04433351 |
| Simple rehabilitation | Other | Approved | Aphasia Non Fluent | RECRUITING | NCT04433351 |
| Enriched rehabilitation | Other | Approved | Aphasia Non Fluent | RECRUITING | NCT04433351 |
| Placebo Comparator | Other | Phase PHASE2 | Age-Related Macular Degeneration | TERMINATED | NCT05893537 |
| Active Comparator CT1812 | Other | Phase PHASE2 | Age-Related Macular Degeneration | TERMINATED | NCT05893537 |
| THINC-it Tool | Other | Phase PHASE2 | Major Depressive Disorder | COMPLETED | NCT03053362 |
| Vortioxetine | Other | Phase PHASE2 | Major Depressive Disorder | COMPLETED | NCT03053362 |
| THINC-it Tool | Other | Phase PHASE2 | Major Depressive Disorder | COMPLETED | NCT03053362 |
| Vortioxetine | Other | Phase PHASE2 | Major Depressive Disorder | COMPLETED | NCT03053362 |
| MRI exam | Other | Approved | Epilepsy | COMPLETED | NCT03543267 |
| MRI exam | Other | Approved | Epilepsy | COMPLETED | NCT03543267 |
| Placebo of the Lexical Association Technique | Other | Approved | Multiple Sclerosis | NOT_YET_RECRUITING | NCT07064291 |
| The Lexical Association Technique (LAT) | Other | Approved | Multiple Sclerosis | NOT_YET_RECRUITING | NCT07064291 |
| Placebo of the Lexical Association Technique | Other | Approved | Multiple Sclerosis | NOT_YET_RECRUITING | NCT07064291 |
| The Lexical Association Technique (LAT) | Other | Approved | Multiple Sclerosis | NOT_YET_RECRUITING | NCT07064291 |
| Prolonged Exposure (PE) | Other | Phase PHASE2 | Posttraumatic Stress Disorder | COMPLETED | NCT03827057 |
| Reconsolidation of Traumatic Memories (RTM) | Other | Phase PHASE2 | Posttraumatic Stress Disorder | COMPLETED | NCT03827057 |
| Prolonged Exposure (PE) | Other | Phase PHASE2 | Posttraumatic Stress Disorder | COMPLETED | NCT03827057 |
| Reconsolidation of Traumatic Memories (RTM) | Other | Phase PHASE2 | Posttraumatic Stress Disorder | COMPLETED | NCT03827057 |
| Propulsion Biofeedback Gait Training | Other | Approved | Diabetic Peripheral Neuropathy | RECRUITING | NCT05965336 |
| Plantar Pressure Biofeedback Gait Training | Other | Approved | Diabetic Peripheral Neuropathy | RECRUITING | NCT05965336 |
| Gait Biofeedback | Other | Approved | Diabetic Peripheral Neuropathy | RECRUITING | NCT05965336 |
| Gait Biomechanics | Other | Approved | Diabetic Peripheral Neuropathy | RECRUITING | NCT05965336 |
| Evaluation of Passive Ankle Stiffness | Other | Approved | Diabetic Peripheral Neuropathy | RECRUITING | NCT05965336 |
| Clinical Evaluation | Other | Approved | Diabetic Peripheral Neuropathy | RECRUITING | NCT05965336 |
| Propulsion Biofeedback Gait Training | Other | Approved | Diabetic Peripheral Neuropathy | RECRUITING | NCT05965336 |
| Plantar Pressure Biofeedback Gait Training | Other | Approved | Diabetic Peripheral Neuropathy | RECRUITING | NCT05965336 |
| Gait Biofeedback | Other | Approved | Diabetic Peripheral Neuropathy | RECRUITING | NCT05965336 |
| Gait Biomechanics | Other | Approved | Diabetic Peripheral Neuropathy | RECRUITING | NCT05965336 |
| Evaluation of Passive Ankle Stiffness | Other | Approved | Diabetic Peripheral Neuropathy | RECRUITING | NCT05965336 |
| Clinical Evaluation | Other | Approved | Diabetic Peripheral Neuropathy | RECRUITING | NCT05965336 |
| Placebo | Other | Phase PHASE2 | Mild to Moderate Alzheimer's Disease | COMPLETED | NCT03507790 |
| CT1812 | Other | Phase PHASE2 | Mild to Moderate Alzheimer's Disease | COMPLETED | NCT03507790 |
| Intervention D Placebo | Other | Phase PHASE2 | Post Traumatic Stress Disorder | NOT_YET_RECRUITING | NCT06816433 |
| Intervention D SLS-002 | Other | Phase PHASE2 | Post Traumatic Stress Disorder | NOT_YET_RECRUITING | NCT06816433 |
| Intervention D Placebo | Other | Phase PHASE2 | Post Traumatic Stress Disorder | NOT_YET_RECRUITING | NCT06816433 |
| Intervention D SLS-002 | Other | Phase PHASE2 | Post Traumatic Stress Disorder | NOT_YET_RECRUITING | NCT06816433 |
| Intervention A Placebo | Other | Phase PHASE2 | Post Traumatic Stress Disorder | RECRUITING | NCT05948553 |
| Intervention A Fluoxetine Hydrochloride (HCl) | Other | Phase PHASE2 | Post Traumatic Stress Disorder | RECRUITING | NCT05948553 |
| Intervention A Placebo | Other | Phase PHASE2 | Post Traumatic Stress Disorder | RECRUITING | NCT05948553 |
| Intervention A Fluoxetine Hydrochloride (HCl) | Other | Phase PHASE2 | Post Traumatic Stress Disorder | RECRUITING | NCT05948553 |
| Intervention B Placebo | Other | Phase PHASE2 | Post Traumatic Stress Disorder | NOT_YET_RECRUITING | NCT05948579 |
| Intervention B Vilazodone Hydrochloride (HCl) | Other | Phase PHASE2 | Post Traumatic Stress Disorder | NOT_YET_RECRUITING | NCT05948579 |
| Intervention B Placebo | Other | Phase PHASE2 | Post Traumatic Stress Disorder | NOT_YET_RECRUITING | NCT05948579 |
| Intervention B Vilazodone Hydrochloride (HCl) | Other | Phase PHASE2 | Post Traumatic Stress Disorder | NOT_YET_RECRUITING | NCT05948579 |
| Placebo | Other | Phase PHASE2 | Early Alzheimer's Disease | ACTIVE_NOT_RECRUITING | NCT05531656 |
| CT1812 | Other | Phase PHASE2 | Early Alzheimer's Disease | ACTIVE_NOT_RECRUITING | NCT05531656 |
| Positron emission tomography scan | Other | Approved | Profound Hearing Impairment | COMPLETED | NCT03117413 |
| Positron emission tomography scan | Other | Approved | Profound Hearing Impairment | COMPLETED | NCT03117413 |
| Maximal incremental exercise test | Other | Approved | Beta Thalassemia Transfusion Dependent | RECRUITING | NCT07207577 |
| Maximal incremental exercise test | Other | Approved | Beta Thalassemia Transfusion Dependent | RECRUITING | NCT07207577 |
| Maximal incremental exercise test | Other | Approved | Beta Thalassemia Transfusion Dependent | RECRUITING | NCT07207577 |
| Maximal incremental exercise test | Other | Approved | Beta Thalassemia Transfusion Dependent | RECRUITING | NCT07207577 |
| zervimesine | Other | Preclinical | Dementia With Lewy Bodies | NO_LONGER_AVAILABLE | NCT06961760 |
| Cognitive Control Deprivation Task | Other | Approved | Anorexia Nervosa | RECRUITING | NCT07274722 |
| Cognitive Control Deprivation Task | Other | Approved | Anorexia Nervosa | RECRUITING | NCT07274722 |
| Placebo | Other | Phase PHASE3 | Psychosis | NOT_YET_RECRUITING | NCT06778564 |
| CBD 100 mg/mL Oral Solution | Other | Phase PHASE3 | Psychosis | NOT_YET_RECRUITING | NCT06778564 |
| Placebo | Other | Phase PHASE3 | Psychosis | NOT_YET_RECRUITING | NCT06778564 |
| CBD 100 mg/mL Oral Solution | Other | Phase PHASE3 | Psychosis | NOT_YET_RECRUITING | NCT06778564 |
| Placebo | Other | Phase PHASE3 | Psychosis | NOT_YET_RECRUITING | NCT06778564 |
| CBD 100 mg/mL Oral Solution | Other | Phase PHASE3 | Psychosis | NOT_YET_RECRUITING | NCT06778564 |
| MRI-scanner | Other | Approved | Memory, Episodic | COMPLETED | NCT04562974 |
| MRI-scanner | Other | Approved | Memory, Episodic | COMPLETED | NCT04562974 |
| Placeb | Other | Phase PHASE3 | Treatment Resistant Psychosis | NOT_YET_RECRUITING | NCT07326124 |
| CBD 100 mg/mL Oral Solution | Other | Phase PHASE3 | Treatment Resistant Psychosis | NOT_YET_RECRUITING | NCT07326124 |
| Placeb | Other | Phase PHASE3 | Treatment Resistant Psychosis | NOT_YET_RECRUITING | NCT07326124 |
| CBD 100 mg/mL Oral Solution | Other | Phase PHASE3 | Treatment Resistant Psychosis | NOT_YET_RECRUITING | NCT07326124 |
| Placebo | Other | Phase PHASE1 | Primary Biliary Cholangitis (PBC) | RECRUITING | NCT07304843 |
| golexanolone | Other | Phase PHASE1 | Primary Biliary Cholangitis (PBC) | RECRUITING | NCT07304843 |
| Placebo | Other | Phase PHASE1 | Primary Biliary Cholangitis (PBC) | RECRUITING | NCT07304843 |
| golexanolone | Other | Phase PHASE1 | Primary Biliary Cholangitis (PBC) | RECRUITING | NCT07304843 |
| Placebo | Other | Phase PHASE1 | Primary Biliary Cholangitis (PBC) | RECRUITING | NCT07304843 |
| golexanolone | Other | Phase PHASE1 | Primary Biliary Cholangitis (PBC) | RECRUITING | NCT07304843 |
| Propulsion Biofeedback Gait Training | Other | Approved | Diabetic Peripheral Neuropathy | RECRUITING | NCT06591780 |
| Plantar Pressure Biofeedback Gait Training | Other | Approved | Diabetic Peripheral Neuropathy | RECRUITING | NCT06591780 |
| Clinical Evaluation | Other | Approved | Diabetic Peripheral Neuropathy | RECRUITING | NCT06591780 |
| Propulsion Biofeedback Gait Training | Other | Approved | Diabetic Peripheral Neuropathy | RECRUITING | NCT06591780 |
| Plantar Pressure Biofeedback Gait Training | Other | Approved | Diabetic Peripheral Neuropathy | RECRUITING | NCT06591780 |
| Clinical Evaluation | Other | Approved | Diabetic Peripheral Neuropathy | RECRUITING | NCT06591780 |
| CT1812 | Other | Phase PHASE2 | Dementia With Lewy Bodies | COMPLETED | NCT05225415 |
| Cognitive, behavioral and quality of life assessment | Other | Preclinical | Deafness, Bilateral | NOT_YET_RECRUITING | NCT07500909 |
| neurophysiological assessment | Other | Preclinical | Deafness, Bilateral | NOT_YET_RECRUITING | NCT07500909 |
| Cognitive, behavioral and quality of life assessment | Other | Preclinical | Deafness, Bilateral | NOT_YET_RECRUITING | NCT07500909 |
| neurophysiological assessment | Other | Preclinical | Deafness, Bilateral | NOT_YET_RECRUITING | NCT07500909 |
| Cognitive, behavioral and quality of life assessment | Other | Preclinical | Deafness, Bilateral | NOT_YET_RECRUITING | NCT07500909 |
| neurophysiological assessment | Other | Preclinical | Deafness, Bilateral | NOT_YET_RECRUITING | NCT07500909 |
| Placebo nasal spray | Other | Phase PHASE2 | Cold Exposure | COMPLETED | NCT04738838 |
| Oxytocin nasal spray | Other | Phase PHASE2 | Cold Exposure | COMPLETED | NCT04738838 |
| Placebo nasal spray | Other | Phase PHASE2 | Cold Exposure | COMPLETED | NCT04738838 |
| Oxytocin nasal spray | Other | Phase PHASE2 | Cold Exposure | COMPLETED | NCT04738838 |
| CBSM | Other | Preclinical | Myasthenia Gravis (MG) | NOT_YET_RECRUITING | NCT07512375 |
| CBSM | Other | Preclinical | Myasthenia Gravis (MG) | NOT_YET_RECRUITING | NCT07512375 |
| CBSM | Other | Preclinical | Myasthenia Gravis (MG) | NOT_YET_RECRUITING | NCT07512375 |
| Barber's Standardized Suggestibility Scale | Other | Preclinical | Frontotemporal Dementia, Behavioral Variant | RECRUITING | NCT07531732 |
| UCLA Structured Insight Interview | Other | Preclinical | Frontotemporal Dementia, Behavioral Variant | RECRUITING | NCT07531732 |
| Computerized affective task | Other | Preclinical | Frontotemporal Dementia, Behavioral Variant | RECRUITING | NCT07531732 |
| Computer-based facial expression recognition task | Other | Preclinical | Frontotemporal Dementia, Behavioral Variant | RECRUITING | NCT07531732 |
| Barber's Standardized Suggestibility Scale | Other | Preclinical | Frontotemporal Dementia, Behavioral Variant | RECRUITING | NCT07531732 |
| UCLA Structured Insight Interview | Other | Preclinical | Frontotemporal Dementia, Behavioral Variant | RECRUITING | NCT07531732 |
| Computerized affective task | Other | Preclinical | Frontotemporal Dementia, Behavioral Variant | RECRUITING | NCT07531732 |
| Computer-based facial expression recognition task | Other | Preclinical | Frontotemporal Dementia, Behavioral Variant | RECRUITING | NCT07531732 |
| Barber's Standardized Suggestibility Scale | Other | Preclinical | Frontotemporal Dementia, Behavioral Variant | RECRUITING | NCT07531732 |
| UCLA Structured Insight Interview | Other | Preclinical | Frontotemporal Dementia, Behavioral Variant | RECRUITING | NCT07531732 |
| Computerized affective task | Other | Preclinical | Frontotemporal Dementia, Behavioral Variant | RECRUITING | NCT07531732 |
| Computer-based facial expression recognition task | Other | Preclinical | Frontotemporal Dementia, Behavioral Variant | RECRUITING | NCT07531732 |
| Behavioral Assessment | Other | Preclinical | Language Development | RECRUITING | NCT07531706 |
| Electrophysiological recording | Other | Preclinical | Language Development | RECRUITING | NCT07531706 |
| Behavioral Assessment | Other | Preclinical | Language Development | RECRUITING | NCT07531706 |
| Electrophysiological recording | Other | Preclinical | Language Development | RECRUITING | NCT07531706 |
| Combined endurance and resistance training | Other | Approved | Aging | RECRUITING | NCT06507189 |
| Combined endurance and resistance training | Other | Approved | Aging | RECRUITING | NCT06507189 |
| Combined endurance and resistance training | Other | Approved | Aging | RECRUITING | NCT06507189 |
| Combined endurance and resistance training | Other | Approved | Aging | RECRUITING | NCT06507189 |
| Combined endurance and resistance training | Other | Approved | Aging | RECRUITING | NCT06507189 |
| Combined endurance and resistance training | Other | Approved | Aging | RECRUITING | NCT06507189 |
| Combined endurance and resistance training | Other | Approved | Aging | RECRUITING | NCT06507189 |
| Combined endurance and resistance training | Other | Approved | Aging | RECRUITING | NCT06507189 |
| Combined endurance and resistance training | Other | Approved | Aging | RECRUITING | NCT06507189 |
| C105 | DRUG | Phase PHASE2 | Cognition Disorders | COMPLETED | NCT00529581 |
| Simple cognitive task | BEHAVIORAL | Approved | Post-traumatic Stress Disorders | COMPLETED | NCT02080351 |
| Electronic Digit Symbol Substitution Test (DSST)- (a.k.a. Codebreaker) | OTHER | Approved | Major Depressive Episode | COMPLETED | NCT03999567 |
| Pen and Paper Digit Symbol Substitution Test (DSST) | OTHER | Approved | Major Depressive Episode | COMPLETED | NCT03999567 |
| Sleepio | DEVICE | Approved | Psychotic Disorders | COMPLETED | NCT04180709 |
| Ecopipam | DRUG | Phase PHASE1 | Drug Interaction | COMPLETED | NCT06194864 |
| rifampicin | DRUG | Phase PHASE1 | Drug Interaction | COMPLETED | NCT06194864 |
| Itraconazole | DRUG | Phase PHASE1 | Drug Interaction | COMPLETED | NCT06194864 |
Total products: 322